Plasma concentrations of vascular endothelial growth factor and
basic fibroblast growth factor in lymphoproliferative
disorders.

J 2005

Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.

SMOLEJ, L., C. ANDRÝS, Vladimír MAISNAR, Luděk POUR, J. MALÝ et. al.

Basic information

Original name

Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.

Name in Czech

Hladiny endoteliálního růstového faktoru a fibroblastového růstového faktoru v plazmě u lymfoproliferativních onemocnění

Authors

SMOLEJ, L. (203 Czech Republic), C. ANDRÝS (203 Czech Republic), Vladimír MAISNAR (203 Czech Republic), Luděk POUR (203 Czech Republic, guarantor) and J. MALÝ (203 Czech Republic)

Edition

Acta medica (Hradec Králové), Hradec Králové, Czech Republic, Facultas Medica, Universitas Carolina, 2005, 1211-4286

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/05:00035961

Organization unit

Faculty of Medicine

Keywords (in Czech)

angiogeneze; VEGF; bFGF;

Keywords in English

Angiogenesis; VEGF; bFGF; Leukemia; Lymphoma; Myeloma

Abstract

ORIG CZ

V originále

Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn't find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin's lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients' survival.

In Czech

Publikace shnuje výsledky měření koncentrací plazmatických hladin VEGF a bFGF u pacientů s lymfoproliferativními onemocněními.

Citovat

SMOLEJ, L., C. ANDRÝS, Vladimír MAISNAR, Luděk POUR and J. MALÝ. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta medica (Hradec Králové). Hradec Králové, Czech Republic: Facultas Medica, Universitas Carolina, 2005, vol. 48, No 1, p. 57-58. ISSN 1211-4286.

@article{838218,
   author = {Smolej, L. and Andrýs, C. and Maisnar, Vladimír and Pour, Luděk and Malý, J.},
   article_location = {Hradec Králové, Czech Republic},
   article_number = {1},
   keywords = {Angiogenesis; VEGF; bFGF; Leukemia; Lymphoma; Myeloma},
   language = {eng},
   issn = {1211-4286},
   journal = {Acta medica (Hradec Králové)},
   title = {Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.},
   volume = {48},
   year = {2005}
}

TY  - JOUR
ID  - 838218
AU  - Smolej, L. - Andrýs, C. - Maisnar, Vladimír - Pour, Luděk - Malý, J.
PY  - 2005
TI  - Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.
JF  - Acta medica (Hradec Králové)
VL  - 48
IS  - 1
SP  - 57-58
EP  - 57-58
PB  - Facultas Medica, Universitas Carolina
SN  - 12114286
KW  - Angiogenesis
KW  - VEGF
KW  - bFGF
KW  - Leukemia
KW  - Lymphoma
KW  - Myeloma
N2  - Angiogenesis plays a major role in the development and progression of haematological malignancies. In our study we measured plasma concentrations of key angiogenic activators vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) using comercially available sandwich enzyme-linked immunosorbent assay (ELISA) in 37 patients with lymphoid malignancies and 20 healthy donors. We found a statistically significant increase in bFGF concentrations in patients with B-cell chronic lymphocytic leukemia (B-CLL, n=18) compared to the control group (median 118.8 vs. 9.3 pg/ml, p<0.001). However, we didn't find any significant difference in VEGF concentrations between B-CLL patients and the control group. There was also no significant increase in bFGF or VEGF in patients with multiple myeloma (n=7) and non-Hodgkin's lymphoma (n=12). Our pilot study shows that measurement of angiogenic activators in plasma is a feasible and reproducible method of angiogenesis assessment. Larger studies are needed for correlation between serum and plasma concentrations and detailed statistical evaluation including the impact on patients' survival.
ER  -

SMOLEJ, L., C. ANDRÝS, Vladimír MAISNAR, Luděk POUR and J. MALÝ. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. \textit{Acta medica (Hradec Králové)}. Hradec Králové, Czech Republic: Facultas Medica, Universitas Carolina, 2005, vol.~48, No~1, p.~57-58. ISSN~1211-4286.

Detailed Information on Publication Record